• In April 2026, Sabra Health Care REIT, Inc. reported first-quarter results showing revenue of US$221.75 million and net income of US$40.88 million, alongside a slight year-on-year decrease in earnings per share from continuing operations to US$0.16.
• On the same day, the company also affirmed a quarterly dividend of US$0.30 per share, signaling ongoing cash returns to shareholders despite modest per‑share earnings pressure.
• Next, we’ll examine how Sabra’s higher quarterly revenue alongside its affirmed US$0.30 dividend interacts with its existing investment narrative.

Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.

Sabra Health Care REIT Investment Narrative Recap

To own Sabra, you have to believe in long term demand for senior housing and healthcare real estate, supported by stable rent collection and a maintained dividend. The latest quarter’s higher revenue and steady US$0.30 dividend do not materially change the near term focus on balancing cash returns with a relatively high payout ratio, which remains a key risk if operating performance weakens or tenant coverage tightens.

The most relevant update here is Sabra’s affirmation of its US$0.30 quarterly dividend alongside modest earnings per share pressure. For income focused investors, this underlines how central dividend continuity is to the near term story, but it also keeps attention on whether funds from operations and operator health can support both ongoing payouts and the planned acquisition pipeline without stretching the balance sheet.

Yet behind the reliable US$0.30 dividend, there is an important risk around payout levels and...

Sabra Health Care REIT's narrative projects $1.2 billion revenue and $243.2 million earnings by 2029.

Uncover how Sabra Health Care REIT's forecasts yield a $22.00 fair value, a 6% upside to its current price.

Exploring Other Perspectives

Two fair value estimates from the Simply Wall St Community range from US$22.00 to about US$53.01, showing how far apart individual views can be. When you weigh those opinions against Sabra’s reliance on sustained senior housing demand and a relatively high dividend payout ratio, it becomes even more important to compare several perspectives on how resilient cash flows might really be.

Explore 2 other fair value estimates on Sabra Health Care REIT - why the stock might be worth over 2x more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Sabra Health Care REIT research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Sabra Health Care REIT research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Sabra Health Care REIT's overall financial health at a glance.

Seeking Other Investments?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Find 49 companies with promising cash flow potential yet trading below their fair value.
• The latest GPUs need a type of rare earth metal called Dysprosium and there are only 33 companies in the world exploring or producing it. Find the list for free.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 14 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.